Antiemetic prophylaxis with temozolomide: an audit from a tertiary care center

BACKGROUND: In our previous experience, a significant proportion of patients who received 5-HT(3) antagonist monotherapy with adjuvant temozolomide (150-200 mg/m(2)) had chemotherapy-induced nausea and vomiting (CINV). This is an audit comparing the multiple antiemetic therapies in the prevention of...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Neurooncol Pract
Autori principali: Patil, Vijay M, Chandrasekharan, Arun, Vallathol, Dilip Harindran, Malhotra, Mridul, Abhinav, Ram, Agarwal, Priti, Rajpurohit, Anu, Tonse, Raees, Bhattacharjee, Atanu, Jalali, Rakesh
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2019
Soggetti:
Original Articles
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6899054/
https://ncbi.nlm.nih.gov/pubmed/31832218
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/nop/npz009
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi